Lifetech SCI (01302) announced that on January 7, 2026, its self-developed G-iliacTM Pro Iliac Artery Stent Graft System (G-iliacTM Pro or the Product) received formal registration approval from the National Medical Products Administration (NMPA) of China. This product is indicated for the endovascular treatment of abdominal aortic aneurysms combined with iliac artery aneurysms or isolated common iliac artery aneurysms; it ensures pelvic blood supply by reconstructing the internal iliac artery, providing clinicians with a more mature and comprehensive solution and achieving a systematic upgrade over existing treatment options.
The internal iliac artery is a crucial branch of the common iliac artery, responsible for supplying blood to pelvic organs, gluteal muscles, and the spinal cord. During early endovascular aortic repair (EVAR) procedures, to prevent endoleaks, one or both internal iliac arteries were often embolized, leading to complications such as gluteal claudication, sexual dysfunction, colonic ischemia, rectal necrosis, spinal cord defects, and even paralysis, severely impacting patients' long-term quality of life. Numerous domestic and international guidelines and consensus documents have clearly stated that preserving at least one internal iliac artery during EVAR procedures leads to better patient outcomes.
Iliac branch device (IBD) technology, owing to its advantages of being more physiological, having a low endoleak rate, and high long-term patency, has gradually become the ideal choice for endovascular reconstruction of the internal iliac artery. The G-iliacTM Iliac Artery Bifurcated Stent System (formerly known as the LifeflowTM Iliac Artery Bifurcated Stent System, (G-iliacTM)) received NMPA approval for market launch in 2021, becoming the first finished IBD device product in China and filling a long-standing market gap in the field of endovascular internal iliac artery reconstruction within the country.
Multicenter clinical applications and real-world studies of G-iliacTM have demonstrated excellent performance in terms of safety, patency, and procedural stability, enabling physicians to perform internal iliac artery reconstruction more confidently under complex anatomical conditions. The G-iliacTM Pro system consists of the G-iliacTM Pro Stent Graft and the SilverFlowTM Pro Stent Graft.
Building upon the foundational advantages of the G-iliacTM system—such as the safe and convenient two-component design, the widely adaptable short and long main body designs, multiple access options (contralateral/brachial artery) for physicians, and the excellent flexibility and high long-term patency inherited from the SilverFlowTM's interwoven braid—the G-iliacTM Pro introduces comprehensive upgrades tailored to clinical needs: A low-profile delivery system offers superior flexibility and navigability, providing a better option for patients with narrow access vessels; the delivery system design is more ergonomic, user-friendly, and allows for precise, controlled deployment; the latest hydrophilic coating process ensures smoother delivery and easier device introduction; a braided sheath combined with a soft core optimizes pushability and crossability, handling complex anatomies with confidence; and clearer marker designs aid in accurate intraoperative positioning.
The market approval of this product represents a significant advancement for the Group's mature technology platform. It not only further enhances the Company's portfolio of innovative products in the field of total endovascular minimally invasive aortic treatment but also provides a superior solution for internal iliac artery reconstruction. The Group is also committed to providing the most comprehensive overall solutions for minimally invasive aortic treatment, continuously driving the minimally invasive treatment of complex aortic diseases towards a new stage of development characterized by greater systematization, standardization, precision, and efficiency.
As commercialization efforts progress, the Company will continue to collaborate with industry experts to advance the research, development, and market introduction of more urgently needed medical device products. This will drive the Group's growth in the medical device sector and ultimately benefit a vast number of patients.